TP53 and neoplasm: The two antibodies induced nearly identical survival benefits (Figs. S5D and S5E), confirming the functional integrity of mAvelumab and reinforcing the conclusion that PD-L1 blockade more effectively inhibits tumor progression in the R270H model (median survival: 59 days) compared to the WT p53 model (median survival: 14 days).